Dave
Dave Bloom is CEO and "Blogger in Chief" of SnackSafely.com.
House Passes School Access to Emergency Epinephrine Act
The US House of Representatives has passed the School Access to Emergency Epinephrine Act.
Update to Natalie Giorgi Tragedy
This is an update to our previous story regarding the tragic death of 13-year-old Natalie Giorgi, who accidentally ingested a treat containing peanut butter and suffered a fatal bout of anaphylaxis.
Anaphylaxis Claims 13 Year Old Girl at Campsite
13-year-old Natalie Giorgi died after accidentally ingesting a treat containing peanut butter at a campsite celebration.
Faulty Genes May Prove the Root Cause of Allergies
Research shows that defective genes known to play a role in connective tissue disorders also plays a significant role in the development of allergies and points to a possible treatment.
AANMA Maps the Status of State Epinephrine Legislation
The AANMA maintains the status of state stock epinephrine legislation in an easy to reference US map. Their site provides links to ACE volunteers in each state that provide education, advocacy and outreach.
$25 Auvi-Q Copay Program
Sanofi has instituted a $25 copay program for the purchase of up to two Auvi-Q epinephrine auto-injectors.
Understand the Limitations of the Label
Knowing what the label CAN and CAN'T tell you about the allergen safety of a food product is an important step toward safeguarding your family.
Update to Safe Snack Guide: July 11, 2013
We've added a number of new products and have confirmed the manufacturing processes of a number of existing products via our Manufacturers' Product Portal which is currently in beta test.
A Preview of the SnackSafely.com Manufacturer Partnership Initiative
SnackSafely.com has been developing a platform that will allow us to engage directly with manufacturers to learn much more about how their products are produced.
Update on Allergen Immunotherapy
The American Academy of Allergy, Asthma and Immunology and the European Academy of Allergy and Clinical Immunology have issued a consensus report on the current state of allergen immunotherapy.
